Gilbert Syndrome

About this condition

Gilbert syndrome is a benign, unconjugated hyperbilirubinemia affecting approximately 2-20% of the general population depending on ethnicity. It is caused by reduced activity of UDP-glucuronosyltransferase 1A1 (UGT1A1), the enzyme responsible for conjugating bilirubin to facilitate excretion. The predominant genetic cause is the UGT1A1*28 polymorphism, consisting of seven TA repeats in the TATA box of the UGT1A1 promoter (instead of the typical six), which reduces enzyme expression to approximately 30% of normal. Clinically, Gilbert syndrome itself is benign — patients develop mild jaundice (typically <6 mg/dL bilirubin), which may transiently worsen with fasting, illness, or stress but poses no health risk.

The critical importance of Gilbert genotyping emerges in pharmacogenomic contexts. UGT1A1*28 homozygotes face severe dose-limiting toxicity with multiple chemotherapy agents and antiretroviral drugs. Variant frequencies vary strikingly by ancestry: approximately 26-31% of Caucasians carry at least one *28 allele, while 42-45% of African Americans and higher percentages of Asian populations carry *28 alleles. Additional UGT1A1 variants exist in specific populations — UGT1A1*6 and *7 in East Asian populations; UGT1A1*5 variants in some populations — each with consequences for drug metabolism.

Understanding UGT1A1 status is essential before prescribing drugs that depend on UGT1A1 for metabolism and clearance. A patient with UGT1A1 homozygous poor metabolizer status must have dose reductions pre-planned before therapy begins, not discovered after severe toxicity develops. Genetic counseling should ensure that any patient diagnosed with Gilbert syndrome or identified through UGT1A1 screening has documentation in their medical record and communicates the result to oncology, infectious disease, and other prescribers of UGT1A1-substrate medications.

UGT1A1 variants differ by ancestry: *28 is most common in Europeans; *6 and *7 predominate in East Asian populations; rare variants in other groups can affect enzyme function.

Gene locus: UGT1A1 (2q37.1)

Standard pharmacogenomics panels test only *28. They miss ancestry-specific variants and other functional UGT1A1 mutations.

The variant affecting your drug safety may be population-specific

Standard pharmacogenomics panels test UGT1A1*28, the most common variant in European populations. However, this approach misses clinically significant variants in other ancestry groups: UGT1A1*6 and *7, found predominantly in East Asian populations, also substantially reduce enzyme activity and create identical drug metabolism challenges. Patients of African ancestry, Hispanic ancestry, and other non-European populations carry additional rare variants affecting UGT1A1 function. Standard panel testing creates an ancestry-specific blindness, leaving populations outside European descent without complete genetic information. Whole genome sequencing captures the complete UGT1A1 sequence, providing comprehensive variant detection across all populations.

Your genotype determines safe dosing for cancer and viral disease treatment

The FDA labeling for irinotecan (a topoisomerase I inhibitor used in colorectal, lung, and ovarian cancer) includes a recommendation for UGT1A1 genotyping: patients who are UGT1A1*28 homozygotes require a 25-30% reduction in irinotecan starting dose to avoid severe neutropenia and diarrhea (grade 3-4 toxicity rates are approximately 3-fold higher in homozygotes without dose reduction). Similarly, UGT1A1*28 homozygotes on atazanavir (a protease inhibitor) experience higher rates of hyperbilirubinemia. A documented UGT1A1 genotype in the medical record prevents dose-limiting toxicity and enables safe, effective therapy continuation.

Your liver works fine — just at half speed. But that matters more than you know when chemotherapy begins.